See more : Healthcare Trust, Inc. (HTIBP) Income Statement Analysis – Financial Results
Complete financial analysis of G1 Therapeutics, Inc. (GTHX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of G1 Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- High Fusion Inc. (2NU.F) Income Statement Analysis – Financial Results
- Hunan Changyuan Lico Co.,Ltd. (688779.SS) Income Statement Analysis – Financial Results
- Key Capital Corporation (KCPC) Income Statement Analysis – Financial Results
- LARK Distilling Co. Ltd. (LRKKF) Income Statement Analysis – Financial Results
- Jackson Financial Inc. (JXN) Income Statement Analysis – Financial Results
G1 Therapeutics, Inc. (GTHX)
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.51M | 51.30M | 31.48M | 45.29M | 0.00 | 0.00 | 0.00 | 0.00 | 522.00K | 1.04M |
| Cost of Revenue | 7.20M | 3.75M | 2.02M | 0.00 | 356.00K | 175.00K | 89.00K | 67.23K | 12.73M | 5.02M |
| Gross Profit | 75.32M | 47.55M | 29.46M | 45.29M | -356.00K | -175.00K | -89.00K | -67.23K | -12.21M | -3.98M |
| Gross Profit Ratio | 91.28% | 92.69% | 93.60% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,338.70% | -381.36% |
| Research & Development | 43.71M | 83.32M | 76.23M | 73.27M | 89.00M | 70.68M | 53.88M | 25.16M | 12.73M | 5.02M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 68.49M | 40.04M | 18.60M | 7.09M | 5.23M | 3.22M | 2.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 71.13M | 100.42M | 95.69M | 68.49M | 40.04M | 18.60M | 7.09M | 5.23M | 3.22M | 2.70M |
| Other Expenses | 2.24M | 3.00K | -346.00K | -542.00K | 6.59M | 4.00M | 888.00K | 182.37K | 18.00K | 0.00 |
| Operating Expenses | 114.84M | 183.73M | 171.92M | 141.76M | 129.04M | 89.29M | 60.97M | 30.39M | 15.95M | 2.70M |
| Cost & Expenses | 122.04M | 187.48M | 173.93M | 141.76M | 129.04M | 89.29M | 60.97M | 30.39M | 15.95M | 7.72M |
| Interest Income | 2.47M | 748.00K | 43.00K | 952.00K | 6.59M | 0.00 | 0.00 | 0.00 | 0.00 | 912.00 |
| Interest Expense | 10.04M | 10.43M | 4.67M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 513.00K | 530.00K | 469.00K | 582.00K | 356.00K | 175.00K | 89.00K | 67.23K | 42.00K | 17.31K |
| EBITDA | -39.01M | -134.90M | -142.46M | -95.48M | 0.00 | 0.00 | 0.00 | -30.32M | -15.38M | -6.66M |
| EBITDA Ratio | -47.28% | -262.95% | -453.55% | -212.14% | 0.00% | 0.00% | 0.00% | 0.00% | -2,016.28% | -638.80% |
| Operating Income | -39.53M | -136.18M | -142.46M | -96.48M | -129.04M | -89.29M | -60.97M | -30.39M | -15.42M | -6.68M |
| Operating Income Ratio | -47.91% | -265.45% | -452.59% | -213.04% | 0.00% | 0.00% | 0.00% | 0.00% | -2,954.79% | -640.46% |
| Total Other Income/Expenses | -5.33M | -9.68M | -4.97M | -1.37M | 6.59M | 4.00M | 847.00K | 100.14K | -4.84M | -64.00 |
| Income Before Tax | -44.85M | -145.86M | -147.43M | -97.84M | -122.45M | -85.29M | -60.12M | -30.29M | -20.26M | -6.68M |
| Income Before Tax Ratio | -54.36% | -284.32% | -468.38% | -216.06% | 0.00% | 0.00% | 0.00% | 0.00% | -3,881.80% | -640.46% |
| Income Tax Expense | 3.12M | 1.70M | 925.00K | 1.41M | -356.00K | 4.00M | 41.00K | 82.23K | 4.86M | 502.36K |
| Net Income | -47.97M | -147.56M | -148.35M | -99.25M | -122.09M | -85.29M | -60.12M | -30.29M | -20.26M | -7.18M |
| Net Income Ratio | -58.13% | -287.63% | -471.32% | -219.18% | 0.00% | 0.00% | 0.00% | 0.00% | -3,881.80% | -688.64% |
| EPS | -0.93 | -3.38 | -3.54 | -2.62 | -3.26 | -2.56 | -3.30 | -1.48 | -0.99 | -5.85 |
| EPS Diluted | -0.93 | -3.38 | -3.54 | -2.62 | -3.26 | -2.56 | -3.30 | -1.48 | -0.99 | -5.85 |
| Weighted Avg Shares Out | 51.73M | 43.63M | 41.94M | 37.88M | 37.50M | 33.32M | 18.20M | 20.43M | 20.43M | 1.23M |
| Weighted Avg Shares Out (Dil) | 51.73M | 43.63M | 41.94M | 37.88M | 37.50M | 33.32M | 18.20M | 20.43M | 20.43M | 1.23M |
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
G1 Therapeutics' breast cancer drug fails in late-stage trial
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
Source: https://incomestatements.info
Category: Stock Reports